Clinical Trials Logo

Lysosomal Storage Diseases clinical trials

View clinical trials related to Lysosomal Storage Diseases.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04040049 Terminated - Fabry Disease Clinical Trials

A Fabry Disease Gene Therapy Study

MARVEL1
Start date: July 8, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multinational, open-label study to assess the safety and efficacy of FLT190 in up to 15 adult male participants with classical Fabry disease.

NCT ID: NCT03853876 Terminated - Clinical trials for Lysosomal Storage Diseases

A Natural History Study of Aspartylglucosaminuria

AGU
Start date: April 18, 2019
Phase:
Study type: Observational

Aspartylglucosaminuria (AGU) is a rare neurodegenerative lysosomal storage disease (LSD) characterized by developmental delay, psychomotor regression, worsening intellectual disability, gait disturbance and, ultimately, premature death, and has no available treatments. The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with AGU. This natural history study is important to better understand disease course to be able to determine clinically meaningful outcome measures for use in future clinical trials.

NCT ID: NCT01963650 Terminated - Clinical trials for Nervous System Diseases

Natural History Study of Children With Metachromatic Leukodystrophy

Start date: November 2, 2015
Phase:
Study type: Observational

The purpose of this study is evaluate the natural course of disease progression related to gross motor function in children with metachromatic leukodystrophy (MLD).

NCT ID: NCT00786968 Terminated - Clinical trials for Mucopolysaccharidosis I

Extension Study of Intrathecal Enzyme Replacement Therapy for MPS I

Start date: January 2008
Phase: Phase 1
Study type: Interventional

This is a one-year extension study of the use of laronidase into the spinal fluid to treat spinal cord compression in mucopolysaccharidosis I. Mucopolysaccharidosis I is a rare genetic condition due to deficiency of the enzyme alpha-l-iduronidase. Spinal cord compression occurs in this condition due to accumulation of material called glycosaminoglycans (GAG). Laronidase is the manufactured form of the enzyme alpha-l-iduronidase that is deficient in mucopolysaccharidosis I patients. The aim of this study is to determine whether laronidase is safe and effective when given into the spinal fluid as a potential non-surgical treatment for spinal cord compression due to mucopolysaccharidosis I disease. Funding Source -- FDA OOPD

NCT ID: NCT00654433 Terminated - Clinical trials for Inborn Errors of Metabolism

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

UCBT-002
Start date: March 2008
Phase: Phase 3
Study type: Interventional

Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion. The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.

NCT ID: NCT00215527 Terminated - Clinical trials for Mucopolysaccharidosis I

Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I

Start date: November 2005
Phase: Phase 1
Study type: Interventional

The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD